There are 8 IPOs up on the schedule this week and valuation will continue to be a big focus from IPO investors. Given the recent selloff and reports that a record 80% of IPOs launched this year have lost money, many investors are putting the financials of IPOs under the microscope.
The largest of the week is Solar Winds (NYSE: SWI) which is hoping to raise $756 million. This is a popular IT/Software company with $786 million in sales for the previous 12 months. The company will offer 42 million shares at $17 - $19, which puts them at a $5.5 billion valuation. This IPO accounts for about half of the potential funds raised this week.
Valtech (NASDAQ: VTEC) is another IT company going public this week with their $100 million offering. The UK-based IT outsourcing company shows $256 million in sales in the last 12 months and will offer 6.6 million shares at a range of $14 -$16, giving them about a $670 million valuation.
Riley Exploration Permian (NYSE: REPX) may be the IPO that gets the most attention this week given that's been more than three months since an Oil and Gas IPO came to market. They're looking for $100 million with their offering of 6.7 million shares at a range of $14 -$16. This would give them a valuation of $354 million on $58 million in sales.
Studio City (NYSE: MSC), a resort and casino based in Macau, is being spun out of another company. They have about 90% of the offering spoken for already, but will offer 28 million shares at a range of $10.50 - $12.50 in hopes of raising $331 million.
There is only one China-based offering, Niu Technologies (NASDAQ: NIU), an electric scooter manufacturer. They hope to raise $95 million by offering 8 million shares at a range of $10.50 - $12.50. The young company has $151 million in sales for the previous 12 months.
In the medical/biotech space there are three offerings up for grabs this week. SI-Bone (NASDAQ: SIBN) is a surgical implant firm focused on lower back pain, and is the largest offering in the group. They'll offer 6 million shares at a range of $13 -$15 in hopes of raising $84 million. LogicBio Therapeutics (NASDAQ: LOGC) is developing therapies for rare diseases and is currently in the pre-clinical stage. They'll offer 5.7 million shares in hopes of raising $75 million. Given their current phase of business they have no sales. Finally, PhaseBio Pharmaceuticals (NASDAQ: PHAS) is a biotech firm focused on therapies for orphan diseases. The company is currently in phase 2 and has no sales. They hope to raise $65 million by offering 5 million shares at a range of $12 -$14.